tert-butyl 3-(7-(bis((2-(trimethylsilyl)ethoxy)methyl)amino)pyrazolo[1,5-a]pyrimidin-5-yl)-8-azabicyclo[3.2.1]oct-2-ene-8-carboxylate | 1319255-22-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡唑并嘧啶类
• 英文名称: tert-butyl 3-(7-(bis((2-(trimethylsilyl)ethoxy)methyl)amino)pyrazolo[1,5-a]pyrimidin-5-yl)-8-azabicyclo[3.2.1]oct-2-ene-8-carboxylate
• 英文别名: tert-butyl 3-[7-[bis(2-trimethylsilylethoxymethyl)amino]pyrazolo[1,5-a]pyrimidin-5-yl]-8-azabicyclo[3.2.1]oct-2-ene-8-carboxylate
• CAS: 1319255-22-5
• 化学式: C₃₀H₅₁N₅O₄Si₂
• 分子量: 601.937
• InChiKey: PIKMZQCQZFSOFL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.72
• 重原子数：
  41
• 可旋转键数：
  14
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.7
• 拓扑面积：
  81.4
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  tert-butyl 3-(7-(bis((2-(trimethylsilyl)ethoxy)methyl)amino)pyrazolo[1,5-a]pyrimidin-5-yl)-8-azabicyclo[3.2.1]oct-2-ene-8-carboxylate 在 钯 氢气 、 silica 、 EtOAc Hexanes 作用下， 以 乙酸乙酯 、 EtOAc Hexanes 为溶剂， 反应 16.0h， 生成 tert-butyl anti-3-(7-(bis((2-(trimethylsilyl)ethoxy)methyl)amino)pyrazolo[1,5-a]pyrimidin-5-yl)-8-azabicyclo[3.2.1]oct-2-ene-8-carboxylate
  参考文献：
  名称：

  PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS

  摘要：

  本发明提供了式（I）的吡唑吡咯啉化合物：其中L、T、Z、U、V、W、R3、R6、R7、R8和m如本文所定义，并且这些吡唑吡咯啉化合物的药物可接受的盐。这些吡唑吡咯啉化合物在治疗癌症和其他mTOR失调的疾病或疾病中具有用处。

  公开号：

  US20120322791A1
• 作为产物：
  描述：

  5,7-二氯吡唑并[1,5-A]嘧啶 在 palladium bis[bis(diphenylphosphino)ferrocene] dichloride ammonium hydroxide 、 sodium carbonate 作用下， 以 乙二醇二甲醚 为溶剂， 反应 18.5h， 生成 tert-butyl 3-(7-(bis((2-(trimethylsilyl)ethoxy)methyl)amino)pyrazolo[1,5-a]pyrimidin-5-yl)-8-azabicyclo[3.2.1]oct-2-ene-8-carboxylate
  参考文献：
  名称：

  [EN] FUSED TRICYCLIC INHIBITORS OF MAMMALIAN TARGET OF RAPAMYCIN
  [FR] INHIBITEURS TRICYCLIQUES CONDENSÉS DE MTOR (MAMMALIAN TARGET OF RAPAMYCIN)

  摘要：

  这项发明涉及新颖的融合三环化合物，它们是哺乳动物雷帕霉素靶点（mTOR）激酶的抑制剂，也被称为FRAP、RAFT、RAPT或SEP，并且在治疗细胞增殖性疾病方面有用，例如癌症和其他增殖性障碍。

  公开号：

  WO2012027234A1

文献信息

• [EN] FUSED TRICYCLIC INHIBITORS OF MAMMALIAN TARGET OF RAPAMYCIN<br/>[FR] INHIBITEURS TRICYCLIQUES CONDENSÉS DE MTOR (MAMMALIAN TARGET OF RAPAMYCIN)
  申请人：SCHERING CORP

  公开号：WO2012027234A1

  公开（公告）日：2012-03-01

  This invention relates to novel fused tricyclic compounds that are inhibitors of mammalian Target of Rapamycin (mTOR) kinase, which is also known as FRAP, RAFT, RAPT or SEP, and are useful in the treatment of cellular proliferative diseases, for example cancer and other proliferative disorders.

  这项发明涉及新颖的融合三环化合物，它们是哺乳动物雷帕霉素靶点（mTOR）激酶的抑制剂，也被称为FRAP、RAFT、RAPT或SEP，并且在治疗细胞增殖性疾病方面有用，例如癌症和其他增殖性障碍。
• PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS
  申请人：Siddiqui M. Arshad

  公开号：US20120322791A1

  公开（公告）日：2012-12-20

  The present invention provides Pyrazolopyrimidine Compounds of Formula (I): wherein L, T, Z, U, V, W, R 3 , R 6 , R 7 , R 8 , and m are as defined herein, and pharmaceutically acceptable salts of such Pyrazolopyrimidine Compounds. The Pyrazolopyrimidine Compounds are useful in the treatment of cancer and other diseases or disorders wherein mTOR is deregulated.

  本发明提供了式（I）的吡唑吡咯啉化合物：其中L、T、Z、U、V、W、R3、R6、R7、R8和m如本文所定义，并且这些吡唑吡咯啉化合物的药物可接受的盐。这些吡唑吡咯啉化合物在治疗癌症和其他mTOR失调的疾病或疾病中具有用处。
• FUSED TRICYCLIC COMPOUNDS AS mTOR INHIBITORS
  申请人：Meng Zhaoyang

  公开号：US20140171456A1

  公开（公告）日：2014-06-19

  The present invention relates to certain pyrazolo[1,5-a]pyrrolo[3,2-e]pyrimidine and dipyrazolopyrimidine compounds of Formula (I) as inhibitors of mammalian Target Of Rapamycin (mTOR) kinase, which is also known as FRAP, RAFT, RAPT or SEP. The compounds may be used in the treatment of cancer and other disorders where mTOR is deregulated. The present invention further provides pharmaceutical compositions comprising the pyrazolo[1,5-a]pyrrolo[3,2-e]pyrimidine or dipyrazolopyrimidine compounds.

  本发明涉及某些式（I）的吡唑并[1,5-a]吡咯并[3,2-e]嘧啶和二吡唑嘧啶化合物，作为哺乳动物雷帕霉素靶点（mTOR）激酶的抑制剂，该激酶也被称为FRAP、RAFT、RAPT或SEP。这些化合物可用于治疗癌症和其他mTOR失调的疾病。本发明还提供包含吡唑并[1,5-a]吡咯并[3,2-e]嘧啶或二吡唑嘧啶化合物的制药组合物。
• Fused tricyclic compounds as mTOR inhibitors
  申请人：Meng Zhaoyang

  公开号：US08901142B2

  公开（公告）日：2014-12-02

  The present invention relates to certain pyrazolo[1,5-a]pyrrolo[3,2-e]pyrimidine and dipyrazolopyrimidine compounds of Formula (I) as inhibitors of mammalian Target Of Rapamycin (mTOR) kinase, which is also known as FRAP, RAFT, RAPT or SEP. The compounds may be used in the treatment of cancer and other disorders where mTOR is deregulated. The present invention further provides pharmaceutical compositions comprising the pyrazolo[1,5-a]pyrrolo[3,2-e]pyrimidine or dipyrazolopyrimidine compounds.

  本发明涉及一些式（I）的吡唑并[1,5-a]吡咯并[3,2-e]嘧啶和二吡唑嘧啶化合物，作为哺乳动物雷帕霉素靶（mTOR）激酶的抑制剂，mTOR也被称为FRAP，RAFT，RAPT或SEP。这些化合物可用于治疗癌症和其他mTOR失调的疾病。本发明还提供包含吡唑并[1,5-a]吡咯并[3,2-e]嘧啶或二吡唑嘧啶化合物的药物组合物。
• [EN] FUSED TRICYCLIC INHIBITORS OF MAMMALIAN TARGET OF RAPAMYCIN<br/>[FR] INHIBITEURS TRICYCLIQUES FUSIONNÉS DE LA CIBLE DE LA RAPAMYCINE CHEZ LES MAMMIFÈRES
  申请人：SCHERING CORP

  公开号：WO2012027240A1

  公开（公告）日：2012-03-01

  This invention relates to novel fused tricyclic compounds that are inhibitors of mammalian Target of Rapamycin (mTOR) kinase, which is also known as FRAP, RAFT, RAPT or SEP, and are useful in the treatment of cellular proliferative diseases, for example cancer and other proliferative disorders.

  这项发明涉及新颖的融合三环化合物，它们是哺乳动物雷帕霉素靶点（mTOR）激酶的抑制剂，也被称为FRAP、RAFT、RAPT或SEP，并且在治疗细胞增殖性疾病方面有用，例如癌症和其他增殖性障碍。